Rigel Pharmaceuticals
RIGL
135 hedge funds and large institutions have $503M invested in Rigel Pharmaceuticals in 2018 Q3 according to their latest regulatory filings, with 22 funds opening new positions, 48 increasing their positions, 33 reducing their positions, and 18 closing their positions.
45% more repeat investments, than reductions
Existing positions increased: 48 | Existing positions reduced: 33
22% more first-time investments, than exits
New positions opened: 22 | Existing positions closed: 18
12% more capital invested
Capital invested by funds: $447M → $503M (+$55.7M)
3% more funds holding
Funds holding: 131 → 135 (+4)
0.25% less ownership
Funds ownership: 9.65% → 9.41% (-0.25%)
45% less call options, than puts
Call options by funds: $788K | Put options by funds: $1.43M
Top Buyers
| 1 |
Millennium Management
New York
|
+$13M |
| 2 |
TA
Tamarack Advisers
Carlsbad,
California
|
+$5.78M |
| 3 |
Morgan Stanley
New York
|
+$3.78M |
| 4 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$3.02M |
| 5 |
SI
Sofinnova Investments
Menlo Park,
California
|
+$2.97M |
Top Sellers
| 1 |
MWNA
Marshall Wace North America
New York
|
-$11.5M |
| 2 |
GPP
Great Point Partners
Greenwich,
Connecticut
|
-$9.64M |
| 3 |
SCM
Stonepine Capital Management
Bend,
Oregon
|
-$4.24M |
| 4 |
JP Morgan Chase
New York
|
-$3.82M |
| 5 |
BBA
Baker Bros. Advisors
New York
|
-$2.95M |
RIGL Hedge Fund Activity: Q3 2018 in Review
135 of the 4,374 institutional investors tracked by Wall St. Rank reported a position in Rigel Pharmaceuticals (RIGL) for Q3 2018, worth a combined $503M — up 12% from $447M a quarter earlier.
Buyers outnumbered sellers: 22 funds opened new RIGL positions and 18 closed out — a net gain of 4 holders — while 48 added to existing stakes and 33 trimmed.
The largest buyer was Millennium Management, adding an estimated $13M. The largest seller was Marshall Wace North America, cutting an estimated $11.5M.
- 135 institutional investors held Rigel Pharmaceuticals (RIGL) as of Q3 2018, up from 131 in Q2 2018.
- Funds reported $503M of Rigel Pharmaceuticals stock for Q3 2018, up 12% quarter-over-quarter.
- 22 funds opened new Rigel Pharmaceuticals positions in Q3 2018 and 18 closed out, a net change of +4 holders.
- The largest Rigel Pharmaceuticals buyer in Q3 2018 was Millennium Management, an estimated $13M added.
- The largest Rigel Pharmaceuticals seller in Q3 2018 was Marshall Wace North America, an estimated $11.5M sold.
Based on aggregated 13F filings for Q3 2018.